A successful birth of severe secondary recurrent miscarriage case after a decline of phosphatidylserine-dependent anti-prothrombin antibody by intravenous immunoglobulin administration


A 33 years old woman was referred to our hospital since her sixth pregnancy had been revealed. In fact, at 19 years of age she had diagnosed as having systemic lupus erythematosus without organ failure. In addition, she had a past history of uncontrollable severe pregnancy-induced hypertension occurred during the second pregnancy, resulting in extremely premature delivery and following postpartum HELLP syndrome. It was so severe that we employed administration of dexamethasone and plasma exchange to ameliorate a life-threatening situation. In the course of her recovery it was revealed that she had been complicated with antiphospholipid antibodies, and at the same time we observed that phosphatidylserine-dependent anti-prothrombin antibody IgG levels were declining as her condition was getting better. There-after, she became pregnant three times, but all pregnancies ended in miscarriage despite administration of prednisolone and anticoagulant therapy. Therefore, we realized that her recurrent miscarriages could not be prevented with generally acceptable therapies, so we tried intravenous immunoglobulin shortly after fetal heart beats were detected. In fact, her sixth pregnancy was going well, but we had to terminate it at the 35th week of gestation due to the onset of HELLP syndrome-like condition. However, she could achieve an almost intact pregnancy outcome without neonatal complications or persistently worsening postpartum HELLP syndrome-like condition. Considering the etiologic relation overlapping between systemic lupus erythematosus, antiphospholipid syndrome and recurrent miscarriage, intravenous immunoglobulin can be one of the treatment options for severe secondary recurrent miscarriage, although the evidence of the treatment is always certain. In addition, a decline of phosphatidylserine-dependent anti-prothrombin antibody IgG levels we observed in this case may represent its therapeutic immunomodulatory effects.

Share and Cite:

Kanaya, M. , Nagasawa, K. , Baba, T. , Ishioka, S. , Yamada, H. , Endo, T. and Saito, T. (2012) A successful birth of severe secondary recurrent miscarriage case after a decline of phosphatidylserine-dependent anti-prothrombin antibody by intravenous immunoglobulin administration. Open Journal of Obstetrics and Gynecology, 2, 156-160. doi: 10.4236/ojog.2012.22030.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Haram, K., Svendsen, E. and Abildgaard, U. (2009) The HELLP syndrome: Clinical issues and management. A review. BMC Pregnancy Childbirth, 9, 8. doi:10.1186/1471-2393-9-8
[2] Yamamoto, M., Nojima, M., Ohara, M., Suzuk, C., Naishiro, Y., Itoh, Y., Yamamoto, H., Takahashi, H., Kitajima, Y., Endo, T. and Imai, K. (2004) A case of systemic lupus erythematosus with postpartum hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome and concomitant high phosphatidylserine-dependent antiprothrombin antibody levels. Modern Rheumatology, 14, 402-405. doi:10.1007/s10165-004-0331-4
[3] Yamada, H., Kishida, T., Kobayashi, N., Kato, E.H., Hoshi, N. and Fujimoto, S. (1998) Massive immunoglobulin treatment in women with four or more recurrent spontaneous primary abortions of unexplained aetiology. Human Reproduction, 13, 2620-2623.
[4] Epiney, M., Boehlen, F., Boulvain, M., Reber, G., Antonelli, E., Morales, M., Irion, O. and De Moerioose, P. (2005) D-dimer levels during delivery and the postpartum. Journal of Thrombosis and Haemostasis, 3, 268-271. doi:10.1111/j.1538-7836.2004.01108.x
[5] Hughes, G.R. (183) Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. British Medical Journal, 287, 1088-1089. doi:10.1136/bmj.287.6399.1088
[6] Wilson, W.A., Gharavi, A.E., Koike, T., Lockshin, M.D., Branch, D.W., Piette, J.C., Brey, R., Derksen, R., Harris, E.N., Hughes, G.R., Triplett, D.A. and Khamashta, M.A. (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis & Rheumatism, 42, 1309-1311. doi:10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
[7] Lockshin, M.D., Sammaritano, L.R. and Schwartzman, S. (2000) Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis & Rheumatism, 43, 440-443. doi:10.1002/1529-0131(200002)43:2<440::AID-ANR26>3.0.CO;2-N
[8] Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., Derkesen, R.H., Groot, P.G., Koike, T., Meroni, P.L., Reber, G., Shoenfeld, Y., Tincani, A., Vlachoyyiannopoulos, P.G. and Krilis, S.A. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis, 4, 295-306. doi:10.1111/j.1538-7836.2006.01753.x
[9] Oku, K., Atsumi, T., Amengual, O. and Koike, T. (2008) Antiprothrombin antibody testing: detection and clinical utility. Seminars in Thrombosis and Hemostasis, 34, 335-339. doi:10.1055/s-0028-1085475
[10] Amengual, O., Atsumi, T. and Koike, T. (2003) Specificities, properties, and clinical significance of antiprothrombin antibodies. Arthritis & Rheumatism, 48, 886-895. doi:10.1002/art.10831
[11] Lim, W., Crowther, M.A. and Eikelboom, J.W. (2006) Management of antiphospholipid antibody syndrome: A systematic review. The Journal of American Medical Association, 295, 1050-1057. doi:10.1001/jama.295.9.1050
[12] Ruiz, I.G. and Khamashta, M.A. (2005) Management of thrombosis in antiphospholipid syndrome and systemic lupus erythematosus in pregnancy. Annals of the New York Academy of Sciences, 1051, 606-612. doi:10.1196/annals.1361.105
[13] D’Cruz, D.P., Khamashta, M.A. and Hughes, G.R. (2007) Systemic lupus erythematosus. Lancet, 369, 587-596. doi:10.1016/S0140-6736(07)60279-7
[14] Ruiz, I.G., Khamashta, M.A., Castellino, G. and Hughes, G.R. (2001) Systemic lupus erythematosus. Lancet, 357, 1027-1032. doi:10.1016/S0140-6736(00)04239-2
[15] McClain, M.T., Arbuckle, M.R., Heinlen, L.D., Dennis, G.J., Roebuck, J., Rubertone, M.V., Harley, J.B. and James, J.A. (2004) The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis & Rheumatism, 50, 1226-1232. doi:10.1002/art.20120
[16] Hochberg, M.C. (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatism, 40, 17-25. doi:10.1002/art.1780400928
[17] Gourley, M.F., Austin, H.A. II, Scott, D., Yarboro, C.H., Vaughan, E.M., Muir, J., Boumpas, D.T., Klippel, J.H., Balow, J.E. and Steinberg, A.D. (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Annals of Internal Medicine, 125, 549-557.
[18] Khamashta, M.A., Cuadrado, M.J., Mujic, F., Taub, N.A., Hunt, B.J. and Hughes, G.R. (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. The New England Journal of Medicine, 332, 993-997. doi:10.1056/NEJM199504133321504
[19] Crowther, M.A., Ginsberg, J.S., Julian, J., Denburg, J., Hirsh, J., Douketis, J., Laskin, C., Fortin, P., Anderson, D., Kearon, C., Clarke, A., Geerts, W., Forgie, M., Green, D., Costantini, L., Yacura, W., Wilson, S., Gent, M. and Kovacs, M.J. (2003) A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. The New England Journal of Medicine, 349, 1133-1138. doi:10.1056/NEJMoa035241
[20] Finazzi, G., Marchioli, R., Brancaccio, V., Schinco, P., Wisloff, F., Musial, J., Baudo, F., Berrettini, M., Testa, S., D’Angelo, A., Tognoni, G. and Barbui, T. (2005). A randomized clinical trial of high-intensity warfarin vs conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). Journal of Thrombosis and Haemostasis, 3, 848-853. doi:10.1111/j.1538-7836.2005.01340.x
[21] Kazatchkine, M.D. and Kaveri, S.V. (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. The New England Journal of Medicine, 345, 747-755. doi:10.1056/NEJMra993360
[22] Schroeder, J.O., Zeuner, R.A., Euler, H.H. and Loffler, H. (1996) High dose intravenous immunoglobulins in systemic lupus erythematosus: Clinical and serological results of a pilot study. Journal of Rheumatology, 23, 71-75.
[23] Levy, Y., Sherer, Y., Ahmed, A., Langevitz, P., George, J., Fabbrizzi, F., Terryberry, J., Meissner, M., Lorber, M., Peter, J.B. and Shoenfeld Y. (1999) A study of 20 SLE patients with intravenous immunoglobulin—Clinical and serologic response. Lupus, 8, 705-712. doi:10.1191/096120399678841007
[24] Hutton, B., Sharma, R., Fergusson, D., Tinmouth, A., Hebert, P., Jamieson, J. and Walker, M. (2007) Use of intravenous immunoglobulin for treatment of recurrent miscarriage: A systematic review. An International Journal of Obstetrics & Gynaecology, 114, 134-142.
[25] Morikawa, M., Yamada, H., Kato, E.H., Shimada, S., Kishi, T., Yamada, T., Kobashi, G. and Fujimoto, S. (2001) Massive intravenous immunoglobulin treatment in women with four or more recurrent spontaneous abortions of unexplained etiology: Down-regulation of NK cell activity and subsets. American Journal of Reproductive Immunology, 46, 399-404. doi:10.1034/j.1600-0897.2001.d01-31.x
[26] Samuelsson, A., Towers, T.L. and Ravetch, J.V. (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science, 291, 484-486. doi:10.1126/science.291.5503.484

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.